ArticleThoracic research and practice2023
Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.
Nuran Katgı et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.